| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $2.1M | — | +598.0% |
| SG&A Expense | $49.9M | — | +11.1% |
| Operating Income | -$55.1M | — | -6.2% |
| Interest Expense | $79.2M | — | +191.3% |
| Income Tax | $0 | — | — |
| Net Income | -$195.0M | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $143.1M | -0.5% | +9.3% |
| Current Assets | $487.5M | -32.1% | +20.4% |
| Total Assets | $13.23B | +6.5% | +91.9% |
| Current Liabilities | $1.21B | -9.1% | +155.3% |
| Long-term Debt | $9.36B | +6.0% | +105.6% |
| Total Liabilities |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$110.8M | — | -61.0% |
| Capital Expenditures | $1.18B | — | +52.8% |
| Investing Cash Flow | -$1.18B | — | -51.0% |
| Financing Cash Flow | $1.05B | — | +24.2% |
| Free Cash Flow | -$1.29B | — | -53.5% |
| EPS (Basic) | -$0.51 | — | -50.0% |
| EPS (Diluted) | -$0.51 | — | -50.0% |
| $10.87B |
| +7.4% |
| +110.3% |
| Stockholders' Equity | -$30.7M | -132.2% | -110.2% |